Kymab strengthens management team
This article was originally published in Scrip
Executive Summary
Cambridge, UK-based Kymab, a monoclonal antibody biopharmaceutical company, has named Steve Arkinstall chief scientific officer and Nigel Clark president and head of business development. Mr Arkinstall joins the company from Merck Serono where he held a number of senior management roles including leadership of the Serono Research Institute in Boston as well as head of global technologies and external innovation. He succeeds Allan Bradley as CSO at Kymab. Mr Bradley, a founder of the company, will remain on the executive leadership team.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.